Hepatitis B virus reactivation after effective sofosbuvir and ribavirin treatment in a patient with occult hepatitis B virus infection

Reactivation of the hepatitis B virus (HBV) has been reported in patients with occult infection (OBI), i.e. HBV surface antigen (HBsAg) negative, HBV core antibody (anti-HBc) positive ± antibodies against HBsAg (anti-HBs) and detectable HBV DNA in serum or liver, receiving immunosuppressive or cytot...

Full description

Saved in:
Bibliographic Details
Published in:The New microbiologica 2017-07, Vol.40 (3), p.218-220
Main Authors: Odolini, Silvia, Lanza, Paola, Angiola, Angiola, Zaltron, Serena, Urbinati, Lucia, Vavassori, Andrea, Nasta, Paola, Festa, Elena, Gargiulo, Franco, Rodella, Anna, Caruso, Arnaldo, Casari, Salvatore, Castelli, Francesco, Viganò, Mauro
Format: Article
Language:English
Subjects:
Activation
Aged
Anti-Inflammatory Agents - administration & dosage
Antibodies
Antiviral agents
Antiviral Agents - therapeutic use
Cryoglobulinemia - complications
Cryoglobulinemia - drug therapy
Cytotoxicity
Deoxyribonucleic acid
DNA
DNA, Viral - blood
Female
Genotypes
Guanine - analogs & derivatives
Guanine - therapeutic use
Hepatitis
Hepatitis B
Hepatitis B - complications
Hepatitis B - drug therapy
Hepatitis B Antibodies - blood
Hepatitis B surface antigen
Hepatitis B Surface Antigens - blood
Hepatitis B virus - genetics
Hepatitis C
Hepatitis C - complications
Hepatitis C - drug therapy
Humans
Immunologic Factors - therapeutic use
Immunosuppressive agents
Infections
Interferon
Liver
Patients
Prednisolone - administration & dosage
Recurrence
Ribavirin
Ribavirin - therapeutic use
Rituximab - therapeutic use
Sofosbuvir - therapeutic use
Viral Load
Viruses
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Reactivation of the hepatitis B virus (HBV) has been reported in patients with occult infection (OBI), i.e. HBV surface antigen (HBsAg) negative, HBV core antibody (anti-HBc) positive ± antibodies against HBsAg (anti-HBs) and detectable HBV DNA in serum or liver, receiving immunosuppressive or cytotoxic therapies. Recently, concerns have been raised regarding the risk of HBV reactivation in OBI patients treated with direct acting antiviral agents (DAAs) for chronic hepatitis C (CHC). Here we describe a case of HBV reactivation in a 72-year-old woman with OBI as a possible consequence of effective treatment with sofosbuvir (SOF) and ribavirin (Rbv) for genotype 2a/2c CHC.
ISSN:1121-7138